New Systemic Treatment for Malignant Melanoma

New therapeutical approaches for the treatment of malignant Melanoma

Treatment of metastatic malignant melanoma.

The rapid increase in incidence of malignant melanoma has not been associated with better therapeutic options over the years. Single-agent chemotherapy or immunotherapy remain the treatments of choice when systemic therapy is offered. Dacarbazine (DTIC) is the chemotherapy of choice with a response rate of 16%. Other chemotherapies, including cisplatinum, paclitaxel, docetaxel and the DTIC anal...

Malignant gliomas: old and new systemic treatment approaches

BACKGROUND Malignant (high-grade) gliomas are rapidly progressive brain tumours with very high morbidity and mortality. Until recently, treatment options for patients with malignant gliomas were limited and mainly the same for all subtypes of malignant gliomas. The treatment included surgery and radiotherapy. Chemotherapy used as an adjuvant treatment or at recurrence had a marginal role. CON...

Advanced skin melanoma – systemic treatment

In Poland, morbidity and mortality rates for melanoma are constantly increasing. In the case of inoperable disease or distant metastases, prognosis remains poor. For many years, dacarbazine has been the gold standard in systemic treatment. Recently, a significant progress in melanoma therapy has been observed. Introducing targeted therapy or immunotherapy significantly improved treatment outcom...

Melanoma Treatment and New Alternative Targets for Melanoma Treatment

Melanoma is the most lethal form of skin cancer. Until 2011, the favored therapy was chemotherapy despite their low efficiency. Spectacular progresses were made in melanoma treatment using targeted therapies anti-BRAFV600E / anti-MEK and immunotherapy antiCTLA-4 / anti PD-1. Unfortunately, more than 50% of patients present intrinsic or acquire resistance and are in treatment failure. So identif...